Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:16 PM ET


Company Overview of Hyperion Solutions Corp.

Company Overview

As of April 13, 2007, Hyperion Solutions Corp. was acquired by Oracle Corporation. Hyperion Solutions Corp. provides business performance management software. It offers Hyperion System 9 Planning, a planning, budgeting, and forecasting solution; Hyperion System 9 Workforce Planning, a planning module; Hyperion System 9 Strategic Finance, a financial modeling desktop application; and Hyperion System 9 Financial Management, which delivers financial consolidation, reporting, and analysis in a single solution. The company also provides Hyperion System 9 BI+, which provides interactive Web-based management reporting and analysis capabilities; Hyperion System 9 BI+ Interactive Reporting, which pro...

5450 Great America Parkway

Santa Clara, CA 95054

United States

Founded in 1981

2,864 Employees





Key Executives for Hyperion Solutions Corp.

Hyperion Solutions Corp. does not have any Key Executives recorded.

Hyperion Solutions Corp. Key Developments

Clal Biotechnology Industries Ltd. Sues Hyperion for $200 Million

Clal Biotechnology Industries Ltd. announced that it had filed a $200 million suit against drug company Hyperion and were not based on careful analysis of the alternatives. Hyperion acquired Andromeda, which was developing Type 1 (juvenile) diabetes drug DiaPep277, in June, after several months of stringent professional examinations. But on September 8, Hyperion announced that it was halting development of Andromeda's drug after claiming that the Israeli company's employees had falsified clinical trial results. Following that announcement, Clal Biotechnology's share plunged, and the company announced it was writing off ILS 506 million. Clal Biotechnology announced in its statement of claim that Hyperion's decision to halt development of the drug was unreasonable even if there is a basis for Hyperion's allegations concerning the alleged misconduct by certain Andromeda employees and its external research advisor.

Similar Private Companies By Industry

Company Name Region
Spectrum, Inc. United States
Xinet, Inc. United States
TowerSec Inc. United States
Trade Solution Group, Inc. United States
CENIT North America Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hyperion Solutions Corp., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at